Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07639723 · ClinicalTrials.gov registry record · Phase 4
Aprepitant to Improve Same Day Discharge for TKA
A Phase 4 study, sponsored by Endeavor Health.
- Not yet
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
NCT07639723 is a Phase 4 study that has not yet begun recruiting, run by Endeavor Health. The registered enrollment target is 350 participants.
The verdict
NCT07639723, a Phase 4 study, has not yet begun recruiting, sponsored by Endeavor Health.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
Study Summary
The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.
Interventions
- OTHER Placebo
- DRUG Dexamethasone
- DRUG Ondansetron (Zofran)
- DRUG Aprepitant Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07639723
The ClinicalTrials.gov registry entry for NCT07639723 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07639723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07639723 about?
NCT07639723 is a clinical study titled "Aprepitant to Improve Same Day Discharge for TKA". The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more...
What is the current status of trial NCT07639723?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2026-07. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07639723?
The interventions under investigation include: Placebo (OTHER), Dexamethasone (DRUG), Ondansetron (Zofran) (DRUG), Aprepitant Injection (DRUG).
Who is sponsoring clinical trial NCT07639723?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.